Drugs / KUR-502
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05487651 | Oct 2022 → Dec 2023 | B-cell adult acute lymphocytic leukemia, B-cell childhood acute lymphoblastic leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large B-cell lymphoma | Athenex, Inc. | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KUR-502 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05487651 ↗ |
| Known as | CD19.CAR-aNKT cells | “KUR-502 (CD19.CAR-aNKT cells) consists of transduced allogeneic natural killer T cells (aNKT) genetically modified with additional features to enhance their anti-tumor activity...” NCT05487651 ↗ |
| Action | Deplete | “the product is expected to kill CD19+ tumor cells” NCT05487651 ↗ |
| Modality | Cell therapy | “transduced allogeneic natural killer T cells (aNKT) genetically modified” NCT05487651 ↗ |
| Route | Intravenous | “Following intravenous (IV) infusion” NCT05487651 ↗ |
| Target | CD19 | “kill CD19+ tumor cells” NCT05487651 ↗ |